PE-22-28

ID: pe2228

Aliases: PE 22-28, PE-22-28, shortened spadin analog

Type: compound

Route/form: preclinical/research peptide; no approved human route

Status: research

Evidence level: preclinical

Best data tier: non-human experimental

Support scope: non-human/mechanistic

Source types: preclinical

Linked sources: 2

Broad outcomes: Brain / mood / sleep

Reading note: These are curation notes anchored to linked sources, not a clinical recommendation or protocol.

Targets / mechanism

• TREK-1 potassium channel inhibition
• sortilin/propeptide-derived spadin pathway
• antidepressant-like behavior models

Optimization domains

• brain
• mood
• depression model
• nootropic

Research basis

• Shortened spadin analog data support TREK-1 inhibition and antidepressant-like preclinical activity.
• Clear mechanism makes it worth indexing separately from generic nootropic peptides.

Limits, risks, and missing evidence

• No human antidepressant or cognitive evidence found.
• TREK-1 biology is not the same as a validated clinical antidepressant effect for this peptide.

Risk flags

• preclinical only
• neuroactive
• unapproved context
• psychiatric context

Linked papers, labels, and reviews

1. Shortened spadin analogs display better TREK-1 inhibition, in vivo stability and antidepressant activity
   preclinical / pubmed_pe2228_spadin_2017
   PE 22-28 / shortened-spadin antidepressant mechanism anchor.
2. Spadin, a sortilin-derived peptide, targeting rodent TREK-1 channels: a new concept in antidepressant drug design
   preclinical / pubmed_spadin_trek1_2010
   Parent spadin/TREK-1 mechanistic background for PE-22-28.